摘要
目的:预测卵巢上皮癌体外化疗敏感性与体内疗效的关系。方法:运用MTT法检测7种临床常用化疗药物及6种经验组合方案对卵巢上皮癌的体外抑制率进行了检测并与体内疗效结果进行比较。结果:7种药物抑制率范围为6.25%~51.43%。其中PTX为51.43%最高,TXT为20.29%,DDP为18.57%,TPT为11.63%,ADM为11.43%,GEM8.82%及Vp-166.25%敏感性最差;6种联合方案的抑制率范围在10.00%~35.00%,TPT+PTX+DDP(35.00%)及PTX+DDP(30.00%)较好,其余4种TXT+DDP(20.59%),TPT+DDP(17.65%),GEM+DDP(11.76%)及Vp-16+ADM(10.00%)均较差。本组药物抑制率与试验前是否用过化疗药无关。体内、外敏感及耐药的总符合率为72.86%(51/70),不符合率27.14%(19/70),统计学有显著性差异(P<0.05)。结论:MTT法对卵巢上皮癌的个体化治疗计划有参考价值,能在一定程度上指导临床用药。
Objective: To assess the correlation between the sensitivity of some ehemotherapeutical agents in vitro and the effective rate of clinical treatment. Methods: Seven chemotherapeutieal agents and 6 combined regimens were used to test the inhibition ratio for 70 cases with ovarian epithelial carcinoma using MTT assay in vitro. Results: The effective rates for the agents and combined regimens were 6.25%-51.43% and 10.00%-35.00%, respectively in 7 ehemotherapeutical agents and 6 combined regimens, such as DTX (51.45%), TXT (20.29%), DDP (18.57%), TPT (11.63%), ADM (11.43%) and GEM(8.82%), as well as Vp16 (6.25%). The DTX(51.45%) was the most sensitive agent for ovarian epithelial carcinoma eompared with other 6 agents, especially the last 4, with a statistical significance (P〈0.05) and TDT+DTX+DDP(35.00%), 8DTX+DDP(30.00%) as well as 4 others, TXT+DDP (20.59%) TDT+DDP (17.65%); GEM+DDP (11.76%), Vp16+ADM (10.00%). In the study, there was no correlation between the pharmaceutieal inhibition ratio and the fact whether or not the drug has been used. The in vivo, sensitive and drug-fast coincident rate was 72.86% (51/70) and the discrepancy was 27.14%(19/ 70). There was a statistieal significance (P〈0.05) between the overall eoincidence and the discrepancy. Conclusion: The MTT assay in vitro has a referenced value for the individualized regimens on ovarian epithelioma and can, to some extent, direct the clinieal medication.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2006年第9期521-523,526,共4页
Chinese Journal of Clinical Oncology
关键词
卵巢上皮癌
化学疗法
MTT法
Ovarian epithelial carcinoma Chemotherapy MTT assay